Nuo Therapeutics, Inc. (AURX)
OTC Markets OTCQB
Price as at 30 Sept 2026, 16:13 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nuo Therapeutics, Inc. trades at $1.25. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its AURX data?
Fundamentals for AURX come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:13 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AURX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.